JP2024517658A - １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法 - Google Patents

１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法 Download PDF

Info

Publication number
JP2024517658A
JP2024517658A JP2023564434A JP2023564434A JP2024517658A JP 2024517658 A JP2024517658 A JP 2024517658A JP 2023564434 A JP2023564434 A JP 2023564434A JP 2023564434 A JP2023564434 A JP 2023564434A JP 2024517658 A JP2024517658 A JP 2024517658A
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
mhc class
tmp
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517658A5 (OSRAM
Inventor
ザ サード ロナルド ディー． セイデル
ロドルフォ ジェイ． チャパーロ
チー メン ロー
Original Assignee
キュー バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュー バイオファーマ， インコーポレイテッド filed Critical キュー バイオファーマ， インコーポレイテッド
Publication of JP2024517658A publication Critical patent/JP2024517658A/ja
Publication of JP2024517658A5 publication Critical patent/JP2024517658A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023564434A 2021-04-21 2022-04-20 １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法 Pending JP2024517658A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177641P 2021-04-21 2021-04-21
US63/177,641 2021-04-21
PCT/US2022/025547 WO2022226069A1 (en) 2021-04-21 2022-04-20 Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024517658A true JP2024517658A (ja) 2024-04-23
JP2024517658A5 JP2024517658A5 (OSRAM) 2025-04-28

Family

ID=83723127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564434A Pending JP2024517658A (ja) 2021-04-21 2022-04-20 １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法

Country Status (7)

Country Link
US (1) US20240101627A1 (OSRAM)
EP (1) EP4326754A4 (OSRAM)
JP (1) JP2024517658A (OSRAM)
CN (1) CN117337298A (OSRAM)
AU (1) AU2022261908A1 (OSRAM)
CA (1) CA3212762A1 (OSRAM)
WO (1) WO2022226069A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020132365A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020180501A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory antigen-presenting polypeptides and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709356A (zh) * 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
CA2996996A1 (en) * 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
WO2020132366A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132368A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
EP3935080A4 (en) * 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
US20240197846A1 (en) * 2021-04-22 2024-06-20 Cue Biopharma, Inc. Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020132365A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020180501A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory antigen-presenting polypeptides and methods of use thereof

Also Published As

Publication number Publication date
WO2022226069A1 (en) 2022-10-27
CA3212762A1 (en) 2022-10-27
US20240101627A1 (en) 2024-03-28
AU2022261908A1 (en) 2023-10-05
CN117337298A (zh) 2024-01-02
EP4326754A1 (en) 2024-02-28
EP4326754A4 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
JP7827324B2 (ja) インターロイキン－２バリアントおよびその使用方法
AU2015292889C1 (en) Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
KR20230029622A (ko) April 및 baff 억제 면역조절 단백질 및 사용 방법
CN116970061A (zh) T细胞调节性多聚体多肽及其使用方法
JP2019507589A (ja) 自己免疫疾患の治療のために制御性ｔ細胞を選択的に活性化する分子
JP7691927B2 (ja) Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
US20240190933A1 (en) Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof
WO2022099157A1 (en) Antigen presenting polypeptide complexes and methods of use thereof
WO2021195108A1 (en) T cell modulatory polypeptides and methods of use thereof
EP3969058A1 (en) Nk cell-directed chimeric proteins
US20240101627A1 (en) Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
KR20230060514A (ko) 인터루킨-2 뮤테인 및 이의 용도
US20240139298A1 (en) Mhc class ii t-cell modulatory polypeptides and methods of use thereof
US20240270815A1 (en) Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
US20230416321A1 (en) TGF-Beta Polypeptides
HK40090097A (zh) April和baff抑制性免疫调节蛋白及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260511